Sowell Financial Services LLC Boosts Stake in Johnson & Johnson (NYSE:JNJ)

Sowell Financial Services LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 1.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 88,802 shares of the company’s stock after buying an additional 959 shares during the period. Sowell Financial Services LLC’s holdings in Johnson & Johnson were worth $13,976,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Newfound Research LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $28,000. Essex Investment Management Co. LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $37,000. Crewe Advisors LLC increased its stake in shares of Johnson & Johnson by 909.1% in the third quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock worth $50,000 after acquiring an additional 300 shares during the period. Dimension Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth $53,000. Finally, IMA Wealth Inc. grew its position in Johnson & Johnson by 26.8% during the third quarter. IMA Wealth Inc. now owns 478 shares of the company’s stock valued at $71,000 after buying an additional 101 shares during the period. 61.26% of the stock is owned by institutional investors and hedge funds.

In other Johnson & Johnson news, COO Michael E. Sneed sold 54,662 shares of Johnson & Johnson stock in a transaction dated Wednesday, December 9th. The shares were sold at an average price of $152.93, for a total transaction of $8,359,459.66. Following the completion of the sale, the chief operating officer now directly owns 110,741 shares in the company, valued at $16,935,621.13. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.27% of the stock is owned by company insiders.

Several analysts recently commented on the stock. Cantor Fitzgerald raised their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $170.00 to $178.00 and gave the company an “overweight” rating in a research report on Tuesday, December 15th. BidaskClub upgraded shares of Johnson & Johnson from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 6th. Credit Suisse Group raised their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. Finally, Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Friday, November 20th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $165.50.

NYSE:JNJ opened at $157.89 on Thursday. The company’s 50-day moving average price is $152.86 and its 200-day moving average price is $148.31. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The company has a market cap of $415.65 billion, a P/E ratio of 24.83, a P/E/G ratio of 3.30 and a beta of 0.68. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $161.32.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The company had revenue of $21.08 billion for the quarter, compared to the consensus estimate of $20.15 billion. During the same period in the previous year, the firm earned $2.12 earnings per share. Johnson & Johnson’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post 7.99 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 9th. Shareholders of record on Tuesday, February 23rd will be given a dividend of $1.01 per share. This represents a $4.04 dividend on an annualized basis and a dividend yield of 2.56%. The ex-dividend date of this dividend is Monday, February 22nd. Johnson & Johnson’s dividend payout ratio is presently 46.54%.

Johnson & Johnson Company Profile

Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Story: Certificate of Deposit (CD) For Risk Adverse Investors?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.